Dendy Young is the Managing Partner of McLean Capital, LLC, a private equity firm, based in McLean, VA, which focuses on investments in early-stage companies. He is also a member of Blu Venture Investors, an angel investment company that supports early stage companies in the Washington DC area through which he has built a portfolio of more than 15 young companies.

From January 1996 to 2006, Mr. Young was CEO of GTSI Corp. (NASDAQ: GTSI), a $1+ billion enterprise services and solutions provider. Prior to GTSI, Mr. Young served as Founder and Chief Executive Officer of Falcon Microsystems, Inc. and, before that, Falcon Systems, Inc.

Mr. Young serves on the Executive Committee of the Northern Virginia Technology Council (NVTC). He is Chairman of the Board of Qlarion, Inc., which provides innovative business analytics to government, and Perthera Inc. which is commercializing a breakthrough in personalized medicine for patients with cancer, and is on the Board of Public Relay, Inc.

Mr. Young lives in McLean, Virginia with his wife, Andrea. He holds a SB in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology and an MBA from the Harvard Business School.

Dr. Bing Yao is the CEO of Viela Bio, a spinoff from MedImmune. He has 20 years’ experience in the biopharmaceutical industry, with a track record of leading successful discovery and development of multiple biotherapeutics. He has served in key leadership roles in and lent critical contribution to the development and approval of multiple biologic products including: IMFINZI, FASENRA, and Siliq.
Previously, Dr. Yao has served as the SVP of MedImmune, Head of Respiratory, Inflammation and Autoimmune and the Former Head of Immuno-oncology Franchise of AstraZeneca. In addition, he has former leadership roles with Genentech and Tanox.

Jacob Vogelstein is a Partner and Portfolio Manager at Camden Partners Holdings, LLC, where he focuses on Camden’s seed strategy. He currently serves on the board of Cage Pharmaceuticals, eNeura, Mind-X and Metabolon. Prior to joining Camden, Jacob was a founding partner of the seed-stage venture capital firm Gamma 3, LLC, and a Program Manager at the Intelligence Advanced Research Projects Activity, where he made investments in high-risk, high-reward research to benefit the US Intelligence Community. Earlier in his career, Jacob served on the faculty at Johns Hopkins University, in both the Applied Physics Laboratory and the Whiting School of Engineering.

Jacob has received widespread recognition for his innovative work in biomedical engineering over the past decade.  In 2017, he was awarded the Presidential Early Career Award in Science and Engineering.  He has been an invited speaker for diverse audiences ranging from BBC News to the President’s Council of Advisors on Science and Technology, has authored over 50 peer-reviewed publications, and has three patents pending in the fields of neuroprosthetics and brain-machine interfaces.

Jacob earned a Sc.B. degree from Brown University in Bio-Electrical Engineering and a Ph.D. degree in Biomedical Engineering from the Johns Hopkins University School of Medicine.

Amitabh Varshney is a Professor of Computer Science and Dean of the College of Computer, Mathematical, and Natural Sciences at the University of Maryland, College Park. In his research, Varshney explores applications of high-performance computing and visualization in engineering, science, and medicine. He has worked on a number of research areas including visual saliency, summarization of large visual datasets, and visual computing for big data. He is currently exploring applications of virtual and augmented reality in several applications, including healthcare and telemedicine. Varshney is a Fellow of IEEE and has served in various roles on the IEEE Visualization and Graphics Technical Committee, including as its Chair (2008–2012). He also received the IEEE Visualization Technical Achievement Award in 2004.

Dr. Jeffrey Ulmer received his B.Sc. with honors from the Department of Chemistry at the University of Regina and was the recipient of the Merit Award of the Society of Chemical Industry of Canada. He received his Ph.D. in biochemistry from McGill University and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. At Merck Research Laboratories, Chiron Corporation and Novartis Vaccines he conducted seminal studies on nucleic acid vaccines and novel vaccine adjuvants/delivery systems. He has published over 200 scientific articles, is on the editorial boards of Expert Opinion on Biological Therapy, Human Vaccines, and Expert Review of Vaccines. He is currently Head, Preclinical R&D, GSK Vaccines.

 John Trainer is the leader of AstraZeneca’s Partnering and Strategy group, which focuses on business deals ranging from acquisitions and clinical collaborations to licensing agreements and new industry partnerships. 

John has held several leadership positions with MedImmune and AstraZeneca during his 14+ years with the company. Previous to this role he was Vice President, Corporate Development for AstraZeneca and earlier the Head for Infection, Neuroscience and Gastrointestinal (ING) medicines within the AstraZeneca global commercial organization (GPPS). Before that, John held a variety of roles across the commercial, strategic and transaction teams at MedImmune. 

John lives in Virginia. He received his MBA from Harvard Business School and his BA from Harvard College. 

Mike is a Director of Inova Personalized Health Accelerator. He is responsible for identifying and investing in all IPHA companies and expediting their achievement of value creating milestones.

As a healthcare technology CEO, Mike raised $125 million in capital and drove shareholder returns that ranged from 4x to 80x, including one IPO and one acquisition. Mike was most recently the founder and CEO of Appian Medical, a digital health firm that served the sleep apnea market. Previously, Mike was CEO of iSonea Ltd (ASX:ISN), a publicly traded global, mobile health app developer and medical device manufacturer in the respiratory disease market, where he increased the company’s market capitalization from $4MM to $250MM.

He is currently a member of the Board of Directors for Circadiance LLC, a specialty CPAP mask manufacturer and is a former board member of AdvaMed, the global medical device association.

Dr. Summar is well-known for his pioneering work in caring for children diagnosed with rare diseases. He joined Children’s National in 2010 from Vanderbilt University. At Children’s National he leads the Division of Genetics and Metabolism, currently the largest known clinical division seeing over 8000 patients a year with rare diseases. Dr. Summar’s laboratory works on both devices and treatments for patients with genetic diseases and adapting knowledge from rare diseases to mainstream medicine. His work has resulted in new drugs in FDA trials for patients with congenital heart disease. His laboratory is best known for its work in the rare diseases affecting nitrogen and ammonia metabolism. Dr. Summar has also organized and led a large number of international work groups to develop standards of care and treatment for rare diseases resulting in significant improvements in outcomes.   Dr. Summar developed a program with NIH where very young children can benefit from NIH research programs at Children’s National. He has been listed with Best Doctor’s in America since 2004. He directs the National Organization for Rare Disorders Scientific and Medical Advisory Committee and leads a program between NORD and the FDA that created a platform for rare disease natural history studies with over 20 already deployed. He is very active in newborn screening issues developing testing and follow-up systems. He has developed and launched at Children’s the world’s first Rare Disease Institute.   This RDI focuses on developing the clinical care field of the over 7000 rare diseases currently recognized. The RDI is the first Clinical Center of Excellence designated by NORD and focuses on building best clinical practices and diagnostic pathways.

Todd Stottlemyer leads the 117-acre Inova Center for Personalized Health campus, which includes the Inova Schar Cancer Institute and the Inova Translational Medicine Institute. Stottlemyer also provides executive leadership for Inova’s research efforts, the Inova Strategic Investment Initiative (venture fund), the Inova Personalized Health Accelerator, Inova’s real estate, and government relations.

Stottlemyer was previously CEO of Acentia, LCC, a private equity backed provider of information technology solutions. Before Acentia, Stottlemyer served as CEO, CFO, and as a member of the executive management teams of three technology companies, two of which were private equity backed and two were publicly traded. Stottlemyer also served as CEO of the National Federation of Independent Business, the nation’s largest business association, and as President of McGuireWoods Consulting.

Stottlemyer has been recognized by Washington Smart CEO magazine as one of their 20 “Most Admired CEOs” in the Washington, DC region; by Washingtonian magazine as one of the Washington, DC region’s top 100 Tech Titans; and by Virginia Business magazine as one of the 50 “most influential Virginians.”

Stottlemyer has served on numerous corporate (publicly traded and private equity and venture backed) and civic boards, including serving as Chair of the Northern Virginia Technology Council (NVTC) and as Chair of the Northern Virginia Chamber of Commerce. Stottlemyer currently serves as Rector (chair) of The College of William & Mary.

Stottlemyer earned his B.A. from The College of William & Mary and a J.D. from the Georgetown University Law Center.